Thrombocytopenia is a common adverse event associated with the HER2-targeted antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (T-DXd). This evidence concerns the gene ERBB2 and Thrombocytopenia.